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Abstract Glycosaminoglycan attachment to perlecan domain I
(173 residues) was completely prevented by site-directed
mutagenesis of Ser-65, Ser-71 and Ser-76 as shown by
recombinant production in mammalian cells. This did not
interfere with the proper folding of the domain’s SEA module
but enhanced its sensitivity to neutral proteases. Lack of
substitution also abolished binding to the two major heparin
binding sites of laminin-1.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Perlecan is an abundant proteoglycan of basement mem-
branes and other pericellular matrices and is usually modi¢ed
by three glycosaminoglycan (GAG) chains attached to one
end of its elongated core protein [1,2]. These side chains, in
particular heparan sulfate, can bind ¢broblast growth factor-2
(FGF-2) which is important in the regulation of cytokine
action during wound healing and angiogenesis [3^6]. They
may also modulate integrin-mediated cell adhesion to perlecan
[7,8] and integrate it into basement membrane structures by
binding to laminin-1 and collagen IV [9].
The major GAG attachment sites of perlecan were localized
to its N-terminal domain I in several recombinant studies
[5,10^12]. They were shown to be substituted by heparan
and chondroitin/dermatan sulfate chains which were, how-
ever, smaller than those of tissue-derived perlecan. A further,
probably minor attachment site which exists on the C-termi-
nal perlecan domain V may be important in the regulation of
cell adhesion and heparin binding [13]. Three serines within
typical SGD consensus sequences of domain I could be iden-
ti¢ed as GAG-linked attachment sites by biochemical analysis
of a recombinant fragment [11] and by site-directed mutagen-
esis of a truncated domain I segment [12]. The latter lacked
the SEA module, which is considered to be associated with
regions of extensive GAG- or O-linked carbohydrate modi¢-
cation in several proteins [14].
In order to study the structure and function of domain I
and its SEA module we have now prepared a recombinant
fragment in which GAG modi¢cation was completely abol-
ished by alanine mutagenesis of Ser-65, Ser-71 and Ser-76.
This fragment I mutant was obtained in high yields and had
a SEA module which was properly folded but became dis-
tinctly sensitive to cleavage by neutral proteases. The mutant
also failed to bind to laminin-1 but retained perlecan-speci¢c
immunological epitopes which could be detected in tissues.
2. Materials and methods
2.1. Expression vector and transfection
The introduction of three mutations in the perlecan domain I
cDNA followed previously used strategies [15]. The overlapping com-
plementary primers 5P-AGCAGGAGATGGCCTTGGCGCCGGA-
GATGTGGGCGCCGGGGACTTC and 5P-GGCGCCCACATCT-
CCGGCGCCAAGGCCATCTCCTGCTGCATCATCT were used
to change three Ser to Ala codons (underlined) by PCR ampli¢cation
with the corresponding 5P and 3P terminal primers used before in the
production of domain I [11] in order to prepare two subfragments.
These were puri¢ed and used with the terminal primers to produce a
cDNA encoding the entire mutated domain I. After restriction with
NheI and XhoI, this was inserted in frame with the BM-40 signal
peptide of the episomal expression vector pCEP-Pu [16]. The correct
sequence and in-frame insertion were con¢rmed by cycle sequencing
on a 373A DNA sequencer (Applied Biosystems). Transfection of
EBNA-293 cells and selection of cells by puromycin in order to obtain
serum-free medium and to purify the fragment I mutant followed a
previous protocol [16].
2.2. Protein puri¢cation and modi¢cation
Recombinant GAG-substituted perlecan fragments IA and IB and
the fragment I mutant were puri¢ed on DEAE cellulose and Superose
12 as previously described [11]. Proteolytic fragment E3 [17] and re-
combinant fragment K1VI/V [18] corresponded to C- and N-terminal
regions of the laminin K1 chain. Digestions with heparitinase and
chondroitinase ABC [11] and with N-glycosidase F [19] followed pre-
vious procedures. Digestions (24 h, 37‡C) with endoproteinase Glu-C,
trypsin and pancreatic elastase (enzyme:substrate ratio 1:100) were
carried out in 0.05 M Tris-HCl, pH 7.4. Digests were then separated
by reversed phase HPLC on a C18 column with a 0^70% acetonitrile
gradient in 0.1% tri£uoroacetic acid.
2.3. Analytical and immunological methods
Amino acid and hexosamine compositions were determined after
hydrolysis with 6 M and 3 M HCl, respectively, on a Biotronik LC
3000 analyzer. Edman degradation on a 473A sequencer followed the
manufacturer’s instructions (Applied Biosystems). Circular dichroism
(CD) spectra were recorded and evaluated as described before [11].
SDS electrophoresis in 5^20% polyacrylamide gels followed estab-
lished protocols. Immunological assays [11] and indirect immuno-
£uorescence [13] were performed with previously described rabbit
antisera [11,13]. Solid phase binding assays followed a standard pro-
tocol [20].
3. Results
An episomal expression vector was used to produce a per-
lecan fragment I mutant in which the three potential GAG
attachment sites, Ser-65, Ser-71 and Ser-76, were mutated to
Ala. This mutant was readily expressed in human EBNA-293
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cells, as shown by electrophoresis (32 kDa band) of serum-free
conditioned medium and radioimmunoassay (production
15 Wg/ml/day). The recombinant fragment I mutant eluted
from a DEAE cellulose column in a narrow peak at around
0.22 M NaCl (Fig. 1A) and was obtained in puri¢ed form
after molecular sieve chromatography, as shown by electro-
phoresis (Fig. 1B, lane 2). Recombinant perlecan fragments
IA, which contains heparan sulfate, and IB, which contains
heparan/chondroitin sulfate, were previously shown [11] to
run as a broad electrophoretic band of 70^100 kDa and to
elute from DEAE cellulose at 0.33 M and 0.4 M NaCl, re-
spectively. Neither of these GAG-modi¢ed forms could be
detected in the culture medium of the fragment I mutant by
immunological assays (see Fig. 1A). The puri¢ed fragment I
mutant showed a single N-terminal sequence APLAVT with
APLA being derived from the BM-40 signal peptide [11,16],
and contained 4.8 þ 0.5 residues of glucosamine and 4.5 þ 0.4
residues of galactosamine. This is consistent with the modi¢-
cation of one N-linked and ¢ve O-linked oligosaccharide ac-
ceptor sites that are present in domain I [11] and the absence
of GAG substitutions. In addition, a minor 22 kDa fragment
with the starting sequence DDAAGDGL (italics denotes ¢rst
mutation) could be puri¢ed from the culture medium, indicat-
ing that the mutated fragment is sensitive to endogenous pro-
teolysis.
Heparitinase-treated fragment IA shows a single electro-
phoretic band of slightly lower mobility than the mutant
(Fig. 1B, lane 1), presumably due to some residual GAG seg-
ments. Treatment of the mutant with heparitinase or chon-
droitinase ABC did not change electrophoretic mobility while
digestion with N-glycosidase F caused partial conversion to a
30 kDa component (Fig. 1B). The CD spectrum of the mutant
(not shown) was almost identical to that described for frag-
ment IA [11], indicating 18% K helix and 62% L structure.
This is consistent with proper folding of the SEA module,
for which similar contents of secondary structure have been
predicted from the sequence [14].
Correct folding of the mutant was also indicated from ra-
dioimmunoinhibition pro¢les, which were indistinguishable
from those previously shown for fragment IA [11]. Rabbit
antibodies which were a⁄nity-puri¢ed on a column contain-
ing the fragment I mutant were tested for their reaction with
tissue forms of perlecan by immuno£uorescence. On sections
of skeletal muscle, they reacted with endomysium, perimysi-
um, perineurium and small blood vessels (Fig. 2A). The same
staining pattern was observed with antibodies against the
C-terminal domain V of perlecan (Fig. 2B). In kidney, stain-
ing for domain I was observed in glomerular and tubular
basement membranes, mesangium and Bowman’s capsule
and in testis basement membranes around seminiferous tu-
bules were stained (not shown).
The identi¢cation of an endogenous fragment of the mutant
raised the question whether the GAG chains protect domain I
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Fig. 1. Chromatography of perlecan fragment I mutant on DEAE
cellulose (A) and SDS gel electrophoresis of puri¢ed fragments prior
to or after enzymatic digestion (B). A: Serum-free conditioned me-
dium (1 l) was passed over a DEAE column (2.5U25 cm) which
was eluted with a 500 ml linear gradient of 0^0.5 M NaCl, as indi-
cated at the bottom. The e¥uent was monitored for absorbance
(280 nm) and for fragment I concentration (Wg/ml) as determined
by radioimmunoinhibition assay. B: Electrophoresis shows fragment
IA after heparitinase digestion (lane 1) and puri¢ed fragment I mu-
tant prior to (lane 2) and after digestion with heparitinase (lane 3),
chondroitinase (lane 4) or N-glycosidase F (lane 5). The gel was
calibrated with marker proteins (in kDa) shown in the left margin.
Fig. 2. Indirect immuno£uorescence staining of mouse skeletal
muscle by a⁄nity-puri¢ed antibodies against perlecan domains I (A)
and V (B). Bar: 100 Wm.
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from proteolysis. This was examined by cleavage of fragments
IA and IB and of the mutant with trypsin, elastase or endo-
proteinase Glu-C. Electrophoresis demonstrated complete di-
gestion of the mutant while substantial amounts of the pro-
teoglycan bands of IA and IB still persisted (not shown).
Complete digestion of the mutant to small peptides was also
demonstrated by reversed phase chromatography, as shown
for endoproteinase Glu-C (Fig. 3A). The amounts of small
peptides released from fragments IA and IB by the same pro-
tease were considerably smaller. Similar but less marked dif-
ferences were also observed after treatment with trypsin or
elastase. Peptides generated by endoproteinase Glu-C were
used to locate cleavage sites by Edman degradation (Fig.
3B). This demonstrated relatively little cleavage in the region
(positions 22^79) of the mutant preceding the SEA module
despite the presence of three Glu residues. Nine major cleav-
age sites were identi¢ed within the SEA module (positions 80^
194), including almost every Glu position. From the same
digest of fragment IA, only three major cleavage sites could
be detected, with lower yields. They included positions near
the N- and C-termini of the SEA module and one within its
central region (Fig. 3B).
Binding of tissue-derived perlecan to laminin-1, which con-
tains the K1 chain, was previously shown to be mainly medi-
ated by the heparan sulfate chains [9]. This was now examined
with the three variants of recombinant domain I using the
laminin K1 chain fragments K1VI/V and E3, which are derived
from the N- and C-termini, respectively (Fig. 4). A solid phase
assay demonstrated a strong binding of fragment IA to E3
and a 10-fold lower reactivity with K1VI/V. For fragment IB,
binding was similar but at a slightly lower level, probably due
to its lower heparan sulfate content [11]. No substantial reac-
tion could be detected for the fragment I mutant. None of the
perlecan fragments bound to ¢bronectin or vitronectin.
4. Discussion
The N-terminal domain I of mouse perlecan was predicted
to contain a GAG attachment region (positions 22^79) with
three SGD acceptor sites [1,2,21] and a SEA module (posi-
tions 80^193) folded into K helical and L structures [14]. Re-
combinant studies provided chemical [11] and mutational [12]
evidence for the substitution of Ser-65, Ser-71 and Ser-76
within the SGD sequences by heparan and chondroitin sul-
fate, but did not exclude a further acceptor site which might
be under the control of the SEA module. Our present data,
however, do not support this possibility. A further, partial
modi¢cation by heparan/chondroitin sulfate was also found
for perlecan domain V [13]. This GAG substitution was re-
cently localized to a single Ser residue of domain V (M. Fried-
rich and R. Timpl, unpublished) indicating that mouse perle-
can may contain up to four GAG chains.
The data also demonstrated that GAG substitution is not
required for the proper folding and secretion of perlecan do-
main I. The absence of this substitution, however, makes do-
main I distinctly more vulnerable to attack by several neutral
proteases. It has also been shown previously that GAG sub-
stitution can protect tissue-derived perlecan from proteolytic
cleavage by the isolation of a tryptic 16 kDa core protein
fragment carrying most of the GAG side chains [22]. Surpris-
ingly, most of the cleaved peptide bonds could be located to
the SEA module despite the prediction of a high content
(60%) of secondary structure elements [14] as con¢rmed here
by CD spectroscopy. The SEA module has also been identi-
¢ed in the proteoglycan agrin and several other proteins where
it was located adjacent to GAG attachment or mucin-like sites
[14]. This could indicate that carbohydrates are required to
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Fig. 3. HPLC separation of peptides obtained from fragment I by
endoproteinase Glu-C digestion (A) and identi¢cation of peptides
by N-terminal sequencing (B). A: The superimposed pro¢les show
the digests of the mutant (solid line) and IB (dotted line) loaded in
identical amounts onto the C18 column. Asterisks denote the peaks
subjected to sequencing. B: The sequence shows only the SEA mod-
ule within the position numbers indicated. The underlined sequences
represent either full-length peptides (ended by a bar) or a partial se-
quence (ended by an arrowhead) and were determined from the di-
gest of the mutant. A similar analysis of peptides obtained in low
yield from GAG-modi¢ed fragment I determined cleavages only at
positions 95/96, 139/140 and 163/164.
Fig. 4. Solid phase binding assay between perlecan domain I frag-
ments and heparin binding laminin-1 fragments. The laminin frag-
ments E3 (open symbols) and K1VI/V (closed symbols) were used in
immobilized form. Soluble recombinant perlecan fragments were IA
(a,b) IB (O,R) and I mutant (P,S) at the concentrations indi-
cated.
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stabilize SEA modules and protect them against proteolytic
degradation and the extent of substitution may control pro-
teolytic processing. Modi¢cation of domain I by GAG does
not seem to in£uence the recognition of perlecan-speci¢c im-
munological epitopes in the core protein [11]. These epitopes
are also exposed in tissue sections, as shown here, which will
now allow us to analyze possible proteolytic degradation of
domain I during developmental and pathological conditions.
The GAG side chains of perlecan domain I are also in-
volved in binding to FGF-2, which enhances binding to
high a⁄nity FGF cell receptors [4,23,24], and in binding to
other extracellular ligands such as laminin-1 [9]. The latter
interaction could contribute to basement membrane assembly
in addition to links between laminin-1 and the perlecan core
protein via ternary complexes with nidogen-1 [9]. Here we
show that recombinant GAG forms of domain I recognize
the C-terminal region of the laminin K1 chain (fragment E3)
and its N-terminal counterpart (fragment K1VI/V) with a 10-
fold di¡erence in binding activity. A similar di¡erence be-
tween the two laminin fragments was observed in their bind-
ing to perlecan [18], indicating that the recombinant and tis-
sue-derived perlecan structures contain similar binding
epitopes on their heparan sulfate chains despite their substan-
tial di¡erence in size [11]. Yet perlecan shows GAG-mediated
binding to ¢bronectin [9] not found here for recombinant
fragment I. The heparan sulfate chains from both sources
could therefore be used to distinguish between di¡erent
GAG binding epitopes in various protein ligands [23,24].
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